Evaluating the Cost-Effectiveness of Liraglutide 1.8Mg Versus Lixisenatide 20μg for the Treatment of Type 2 Diabetes Mellitus in the Spanish Setting

Value in Health - United Kingdom
doi 10.1016/j.jval.2016.09.1879
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

The Cost-Effectiveness of Dulaglutide Versus Liraglutide in Patients With Type 2 Diabetes Mellitus in Taiwan

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

The Cost-Effectiveness of Canagliflozin Versus Sitagliptin as Third-Line Therapy in Type 2 Diabetes Mellitus (T2dm) in a Canadian Setting

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Assessment of the Key Drivers of Cost-Effectiveness in the Economic Modelling of Canagliflozin (CANA) Versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Cost-Effectiveness Analysis of Linagliptin Versus Sulfonylurea as Add-On Treatment to Metformin for the Treatment of Diabetes Mellitus Type 2 Patients in Indonesia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden

Applied Health Economics and Health Policy
MedicineHealth PolicyEconomicsEconometrics
2017English

The Effect of Treatment Intensification Assumptions on Estimates of Cost-Effectiveness in Type 2 Diabetes Mellitus (T2dm)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Cost–benefit Comparison of Liraglutide and Sitagliptin in the Treatment of Type 2 Diabetes in Thailand

ClinicoEconomics and Outcomes Research
Health PolicyEconomicsEconometricsFinance
2019English

Lixisenatide: Evidence for Its Potential Use in the Treatment of Type 2 Diabetes

Core Evidence
MedicineReviewsReferencesPharmacology
2011English

Cost Effectiveness Evaluation of Canagliflozin in Combination With Metformin in the Treatment of Type 2 Diabetes Mellitus in Poland

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy